Financials Veracyte, Inc.

Equities

VCYT

US92337F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
20.8 USD -0.19% Intraday chart for Veracyte, Inc. -11.11% -24.39%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,364 2,833 2,927 1,703 2,009 1,593 - -
Enterprise Value (EV) 1 1,205 2,485 2,755 1,524 1,793 1,367 1,302 1,211
P/E ratio -103 x -74.2 x -37.1 x -46.5 x -27 x -403 x 184 x 79 x
Yield - - - - - - - -
Capitalization / Revenue 11.3 x 24.1 x 13.3 x 5.74 x 5.57 x 3.93 x 3.55 x 3.23 x
EV / Revenue 10 x 21.2 x 12.6 x 5.14 x 4.97 x 3.37 x 2.9 x 2.46 x
EV / EBITDA -109 x -90.5 x -44.2 x -101 x -30.6 x 48.1 x 25.5 x 15.2 x
EV / FCF -201 x -198 x -74.5 x -1,503 x 52.3 x 81.4 x 28.7 x 18.6 x
FCF Yield -0.5% -0.5% -1.34% -0.07% 1.91% 1.23% 3.48% 5.38%
Price to Book 5.38 x 6.76 x 2.67 x 1.59 x 1.93 x 1.38 x 1.35 x 1.3 x
Nbr of stocks (in thousands) 48,840 57,897 71,043 71,753 73,040 76,448 - -
Reference price 2 27.92 48.94 41.20 23.73 27.51 20.80 20.80 20.80
Announcement Date 2/25/20 2/17/21 2/28/22 2/22/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 120.4 117.5 219.5 296.5 361.1 405.6 448.5 492.9
EBITDA 1 -11.01 -27.44 -62.31 -15.15 -58.61 28.43 50.99 79.82
EBIT 1 -15.13 -35.39 -81.9 -41.08 -85.8 -8.625 8.714 22.76
Operating Margin -12.57% -30.12% -37.31% -13.85% -23.76% -2.13% 1.94% 4.62%
Earnings before Tax (EBT) 1 -12.6 -34.91 -81.65 -36.43 -76.61 -1.153 13.61 25.1
Net income 1 -12.6 -34.91 -75.56 -36.56 -74.4 -4.083 9.756 20.9
Net margin -10.47% -29.71% -34.42% -12.33% -20.61% -1.01% 2.18% 4.24%
EPS 2 -0.2700 -0.6600 -1.110 -0.5100 -1.020 -0.0517 0.1133 0.2633
Free Cash Flow 1 -5.988 -12.55 -37 -1.014 34.26 16.8 45.3 65.2
FCF margin -4.97% -10.68% -16.85% -0.34% 9.49% 4.14% 10.1% 13.23%
FCF Conversion (EBITDA) - - - - - 59.1% 88.85% 81.68%
FCF Conversion (Net income) - - - - - - 464.31% 311.98%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/17/21 2/28/22 2/22/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 67.34 67.78 72.86 75.59 80.3 82.42 90.32 90.11 98.2 96.84 99.99 100.9 107.8 106.8 112
EBITDA 1 -5.929 -8.692 -4.241 -3.356 1.136 -3.828 -1.192 -24.42 -29.17 - 7.8 8.7 11.2 - -
EBIT 1 -12.33 -15.25 -10.73 -9.68 -5.42 -10.5 -8.051 -31.74 -35.51 -4.656 -2.221 -1.168 2.247 1.38 4.13
Operating Margin -18.32% -22.5% -14.73% -12.81% -6.75% -12.74% -8.91% -35.22% -36.16% -4.81% -2.22% -1.16% 2.09% 1.29% 3.69%
Earnings before Tax (EBT) 1 -11.32 -14.46 -9.647 -8.875 -3.441 -8.091 -8.277 -29.77 -30.47 -1.908 -1.583 -0.5287 2.912 1.911 4.662
Net income 1 -10.53 -14.46 -9.532 -8.723 -3.844 -8.091 -8.402 -29.62 -28.29 -1.864 -2.193 -1.278 1.313 1.85 4.577
Net margin -15.64% -21.33% -13.08% -11.54% -4.79% -9.82% -9.3% -32.87% -28.81% -1.92% -2.19% -1.27% 1.22% 1.73% 4.09%
EPS 2 -0.1400 -0.2000 -0.1300 -0.1200 -0.0500 -0.1100 -0.1200 -0.4100 -0.3900 -0.0200 -0.0250 -0.0183 0.0200 -0.005000 0.0250
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/28/22 5/3/22 8/2/22 11/2/22 2/22/23 5/4/23 8/8/23 11/7/23 2/22/24 5/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 159 349 172 179 216 226 291 382
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -5.99 -12.5 -37 -1.01 34.3 16.8 45.3 65.2
ROE (net income / shareholders' equity) -7.89% -10.6% -9.96% -3.37% -7.02% -1.06% 0.31% 1.94%
ROA (Net income/ Total Assets) -6.37% -9.53% -9.19% -3.12% -6.55% -0.7% 0.4% 1.8%
Assets 1 197.8 366.2 822.5 1,172 1,136 583.3 2,439 1,161
Book Value Per Share 2 5.190 7.240 15.40 14.90 14.30 15.00 15.40 16.10
Cash Flow per Share 2 -0.1800 -0.5100 -0.8200 -0.1500 0.6100 0.2300 0.4500 0.7300
Capex 1 2.76 2.84 5.38 8.55 9.96 11.1 10 12
Capex / Sales 2.29% 2.41% 2.45% 2.88% 2.76% 2.74% 2.23% 2.43%
Announcement Date 2/25/20 2/17/21 2/28/22 2/22/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
20.8 USD
Average target price
29.83 USD
Spread / Average Target
+43.43%
Consensus
  1. Stock Market
  2. Equities
  3. VCYT Stock
  4. Financials Veracyte, Inc.